Search results
Results from the WOW.Com Content Network
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California, wholly owned by the Swiss multinational pharmaceutical company, the Roche Group. It became an independent subsidiary of Roche in 2009.
Rank Year Purchaser Target Value (in billions USD) Value (adjusted for inflation) 1 2015 Pfizer: Allergan, plc: 160 206 In November 2015 Pfizer announced it would acquire Allergan, plc for $160 billion ($206 billion, adjusted for inflation).
Later, in September, Genentech announced it would acquire Arrayit Corporation. [ 38 ] On 7 April 2014, Roche announced its intention to acquire IQuum for up to $450 million, [ 39 ] as well as the rights to an experimental drug (ORY-1001) from Spanish company Oryzon Genomics for $21 million and up to $500 million in milestone payments. [ 40 ]
Kleiner and Perkins provided $100,000 on the May closing, and acquired 20,000 shares of preferred stock from Genentech. [6] Swanson was made the president and treasurer of Genentech, and received a $2,500 per month salary, along with 25,000 shares. [6] This marked the end of Swanson's unemployment, and the beginning of his career at Genentech ...
Mere rumors that a biotech stock could get bought out can send shares surging. Chances are that a few biotech companies will be scooped up by larger players over The word gets biotech investors ...
From January 2008 to December 2012, if you bought shares in companies when Kenneth M. Duberstein joined the board, and sold them when he left, you would have a -32.1-32.1
Plavix. This anti-clot or blood thinner most prescribed to prevent heart attack or stroke claims the title of second-best selling drug in the world, with $9.4 billion in global sales in 2010.
In January 2014, Galena bought Mills Pharmaceuticals. [14] In April 2014, the company headquarters moved to Portland. [15] In November 2011, the company partnered with Genentech to combine drugs from each company for a cancer treatment. [16] [17] Galena is currently studying the combination of NeuVax and Herceptin in phase II trials. [18]